Skip to main content

Table 3 Impact of [18F]flutemetamol PET on patient management according to clinical diagnosis prior to PET

From: Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Pre-PET etiology AD
(n = 145)
FTD
(n = 28)
OD
(n = 19)
NN
(n = 20)
PET result Positive Negative Positive Negative Positive Negative Positive Negative
n 111 34 6 22 8 11 9 11
AD medication 39 (35%)a 1 (3%) 3 (50%)a 0 (0%) 1 (13%) 0 (0%) 6 (67%)a 1 (9%)
Care 12 (11%) 1 (3%) 1 (17%) 1 (5%) 0 (0%) 0 (0%) 4 (44%) 3 (27%)
Ancillary investigations 0 (0%) 13 (38%)b 1 (17%) 3 (14%) 1 (13%) 2 (18%) 0 (0%) 2 (18%)
  1. Data are presented as n (%). Differences between impact of positive and negative PET results were assessed using χ2 tests
  2. aPositive PET > negative PET, P < 0.05
  3. bNegative PET > positive PET, P < 0.05
  4. PET positron emission tomography, AD Alzheimer’s disease dementia, FTD frontotemporal dementia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis